Zeta PMS-2 Antibody. Zeta’s recombinant rabbit antibody recognizes PMS-2, a tumor suppressor protein involved in DNA mismatch repair. PMS-2 forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene loci of PMS-2 or MLH1 can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. PMS-2 antibody screening by IHC showing loss of nuclear staining suggests microsatellite instability as the lack of staining is usually due to mutations in MLH-1.
HNPCC is an autosomal, dominantly inherited disease associated with a marked increase in cancer susceptibility amd is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological, and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented, and cafe au lait spots.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.